- Home
- TPST vs VYNE Comparison
TPST vs VYNE Comparison
Compare TPST & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | VYNE |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 12.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TPST | VYNE |
|---|---|---|
| Price | $2.95 | $0.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | 119.2K | ★ 14.8M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $2.87 | $0.28 |
| 52 Week High | $13.65 | $4.30 |
Technical Indicators
Market Signals| Indicator | TPST | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 27.63 | 71.15 |
| Support Level | $2.87 | $0.56 |
| Resistance Level | $3.20 | $0.75 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.24 | 0.02 |
| Stochastic Oscillator | 27.78 | 57.48 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.